EyePoint, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| EYPT | SIGHT.PA | YDES | KPRX | OCGN | OCUL | |
|---|---|---|---|---|---|---|
| Market cap | 33.12M | 17.24M | 492.28M | 7.34M | 296.55M | 1.57B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.2 | -0.1 | — | -0.7 | -3.5 | -4.8 |
| Price/book | 0.2 | -0.5 | 110.3 | 0.6 | -16.8 | 3.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −96.37% | −48.74% | −39.33% | −26.07% | −36.59% | −36.91% |
| Today | −1.23% | +1.59% | +7.84% | −4.05% | +17.35% | +4.69% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All EYPT news ›EyePoint: DME Upside Remains, But Financing Could Consume Most Of It (Rating Downgrade)
EyePoint is downgraded from a speculative Strong Buy to a Hold following LUCIA’s failure, pending greater clarity on cash runway. Read more on EYPT stock here. - EyePoint is downgraded from a speculative Strong Buy to a Hold following…
EyePoint Pharmaceuticals (EYPT) was downgraded to a Hold Rating at JonesTrading
EyePoint Pharmaceuticals received a Hold rating and price target from JonesTrading analyst Debanjana Chatterjee today. Chatterjee covers the Healthcare sector, focusing on stocks such as Contineum Therapeutics, Inc. Class A, EyePoint…
More from 1 other outlet
EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals
Oct 20, 2026, 10:09 ET EyePoint described its Phase 3 wet AMD trials as designed in close alignment with the FDA. LUCIA then missed its primary endpoint, and LUGANO's favorable result depended on excluding nine DURAVYU patients. You may…
EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD
- LUCIA did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label aflibercept control, despite demonstrating visual improvement- - Key secondary endpoints in LUCIA were met including a…
EyePoint Cuts Workforce by Half as Part of Strategic Shift
WATERTOWN, Mass.—EyePoint Inc. (Nasdaq: EYPT), a clinical-stage biopharmaceutical company, announced a strategic plan to reduce operating expenses and focus resources on its late-stage Duravyu program for diabetic macular edema (DME).…
EyePoint, Inc. (EYPT) Discusses LUCIA Phase III Topline Results for DURAVYU in Wet Age-Related Macular Degeneration - Slideshow
2026-10-21. The following slide deck was published by EyePoint, Inc. The following slide deck was published by EyePoint, Inc. in conjunction with this event.
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Keeps “Underweight” Rating at JPMorgan Chase & Co.
Posted by Defense World Staff on Oct 21st, 2026 JPMorgan Chase & Co. restated their underweight rating on shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT – Free Report) in a research report released on Tuesday morning, Marketbeat.com…
EyePoint to halve workforce after experimental drug fails second late-stage trial
EyePoint on Monday said it would cut about 53% of its workforce and stop studies of its experimental drug for an age-related vision disease after a second late-stage trial failed. Its... EyePoint to halve workforce after experimental drug…
EyePoint: Stock Takes Shellacking On Second Pivotal Eye Disease Study Miss
EyePoint stock crashed 85% after Duravyu missed a Phase 3 wet AMD endpoint. Click here to read my most recent analysis of EYPT stock. - EyePoint Inc. shares plunged over 85% after Duravyu failed to meet the primary endpoint in the LUCIA…
EyePoint will halve workforce, end pivotal wet AMD trials early following second fail
EyePoint had 214 employees as of Feb. 27, according to an annual report, meaning the layoffs could affect 113 people. Following the news, the biotech’s stock plummeted more than 80% at market open to 55 cents per share. EyePoint first…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com12
- stocktitan.net4
- themarketsdaily.com4
- seekingalpha.com3
- defenseworld.net2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 38 articles, not a forecast.